In fact, a Phase I human clinical trial has recently begun recruiting for the use of ETH-155008, a triple inhibitor to Pim-3, FLT3, and CDK4/6 in the treatment of relapsed/refractory AML, CLL/SLL, and B-cell NHL. The gene discussed is FLT3; the disease is acute myeloid leukemia.